Renal Cancer - Results from #960

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. May 11, 2023

Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study. May 11, 2023

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. May 10, 2023

The effectiveness of partial versus radical nephrectomy for pT3aN0M0 renal cell carcinoma: A propensity score analysis. May 10, 2023

A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma. May 9, 2023

Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy. May 9, 2023

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy. May 8, 2023

A Novel Metric for Hospital Quality in Kidney Cancer Surgery: A Veterans Affairs National Health System Validation of Concept. May 8, 2023

Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells. May 5, 2023

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States. May 5, 2023

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. May 4, 2023

SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. May 4, 2023

STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma. May 3, 2023

Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma. May 3, 2023

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma. May 2, 2023

Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing. May 2, 2023

Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome. May 1, 2023

Long term experience of robotic retroperitoneal partial nephrectomy as the default approach in the management of renal masses: should the paradigm shift? May 1, 2023

How to manage renal masses in kidney transplant recipients? A collaborative review by the EAU-YAU kidney transplantation and renal cancer working groups. April 28, 2023

Evaluation of Growth Rates for Small Renal Masses in Elderly Patients Undergoing Active Surveillance. April 28, 2023

Page 49 of 457